LIVIVO - Search results -

Search results

Result 1 - 10 of total 73

Search options

Article ; Online: Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice.

Kim, In-Jeong / Tighe, Michael P / Lanthier, Paula A / Clark, Madeline J / De La Barrera, Rafael A / Dussupt, Vincent / Mendez-Rivera, Letzibeth / Krebs, Shelly J / Travis, Kelsey L / Low-Beer, Timothy C / Cookenham, Tres S / Lanzer, Kathleen G / Bernacki, Derek T / Szaba, Frank M / Schneck, Amanda A / Ward, Jerrold / Thomas, Stephen J / Modjarrad, Kayvon / Blackman, Marcia A

NPJ vaccines

2024 Volume 9, Issue 1, Page(s) 32

Abstract: Zika virus (ZIKV) is a significant threat to pregnant women and their fetuses as it can cause severe birth defects and congenital neurodevelopmental disorders, referred to as congenital Zika syndrome (CZS). Thus, a safe and effective ZIKV vaccine for ... ...

Abstract	Zika virus (ZIKV) is a significant threat to pregnant women and their fetuses as it can cause severe birth defects and congenital neurodevelopmental disorders, referred to as congenital Zika syndrome (CZS). Thus, a safe and effective ZIKV vaccine for pregnant women to prevent in utero ZIKV infection is of utmost importance. Murine models of ZIKV infection are limited by the fact that immunocompetent mice are resistant to ZIKV infection. As such, interferon-deficient mice have been used in some preclinical studies to test the efficacy of ZIKV vaccine candidates against lethal virus challenge. However, interferon-deficient mouse models have limitations in assessing the immunogenicity of vaccines, necessitating the use of immunocompetent mouse pregnancy models. Using the human stat2 knock-in (hSTAT2KI) mouse pregnancy model, we show that vaccination with a purified formalin-inactivated Zika virus (ZPIV) vaccine prior to pregnancy successfully prevented vertical transmission. In addition, maternal immunity protected offspring against postnatal challenge for up to 28 days. Furthermore, passive transfer of human IgG purified from hyper-immune sera of ZPIV vaccinees prevented maternal and fetal ZIKV infection, providing strong evidence that the neutralizing antibody response may serve as a meaningful correlate of protection.
Language	English
Publishing date	2024-02-15
Publishing country	England
Document type	Journal Article
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-024-00823-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Treatment-adjusted prevalence to assess HIV testing programmes.

Tippett Barr, Beth A / Lowrance, David / Johnson, Cheryl Case / Baggaley, Rachel Clare / Rogers, John H / Balachandra, Shirish K / Barker, Joseph / Kalua, Thokozani / Bunga, Sudhir / Low-Beer, Daniel / Payne, Danielle / Bulterys, Marc G / Jahn, Andreas

Bulletin of the World Health Organization

2021 Volume 99, Issue 12, Page(s) 874–882

Abstract: Scale-up of human immunodeficiency virus (HIV) testing and antiretroviral therapy (ART) for people living with HIV has been increasing in sub-Saharan Africa. As a result, areas with high HIV prevalence are finding a declining proportion of people testing ...

Abstract	Scale-up of human immunodeficiency virus (HIV) testing and antiretroviral therapy (ART) for people living with HIV has been increasing in sub-Saharan Africa. As a result, areas with high HIV prevalence are finding a declining proportion of people testing positive in their national testing programmes. In eastern and southern Africa, where there are settings with adult HIV prevalence of 12% and above, the positivity from national HIV testing services has dropped to below 5%. Identifying those in need of ART is therefore becoming more costly for national HIV programmes. Annual target-setting assumes that national testing positivity rates approximate that of population prevalence. This assumption has generated an increased focus on testing approaches which achieve higher rates of HIV positivity. This trend is a departure from the provider-initiated testing and counselling strategy used early in the global HIV response. We discuss a new indicator, treatment-adjusted prevalence, that countries can use as a practical benchmark for estimating the expected adult positivity in a testing programme when accounting for both national HIV prevalence and ART coverage. The indicator is calculated by removing those people receiving ART from the numerator and denominator of HIV prevalence. Treatment-adjusted prevalence can be readily estimated from existing programme data and population estimates, and in 2019, was added to the World Health Organization guidelines for HIV testing and strategic information. Using country examples from Kenya, Malawi, South Sudan and Zimbabwe we illustrate how to apply this indicator and we discuss the potential public health implications of its use from the national to facility level.
MeSH term(s)	Adult ; Diagnostic Tests, Routine ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV Testing ; Humans ; Malawi ; Prevalence
Language	English
Publishing date	2021-09-30
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	80213-x
ISSN	1564-0604 ; 0042-9686 ; 0366-4996 ; 0510-8659
ISSN (online)	1564-0604
ISSN	0042-9686 ; 0366-4996 ; 0510-8659
DOI	10.2471/BLT.21.286388
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 215: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ethics committee review of medical audit: a personal view from the United Kingdom.

Low-Beer, T S

Sexually transmitted infections

2001 Volume 77, Issue 1, Page(s) 72

MeSH term(s)	Ethics Committees ; Humans ; Medical Audit/standards ; United Kingdom
Language	English
Publishing date	2001-02
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	1420303-0
ISSN	1472-3263 ; 1368-4973
ISSN (online)	1472-3263
ISSN	1368-4973
DOI	10.1136/sti.77.1.72
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Assessment of country implementation of the WHO global health sector strategy on sexually transmitted infections (2016-2021).

PloS one

2022 Volume 17, Issue 5, Page(s) e0263550

Abstract: Background: In 2016, WHO launched the Global Health Sector Strategy on STIs, 2016-2021 (GHSS) to provide guidance and benchmarks for country achievement by 2020 and four global targets for achievement by 2030.: Methods: A country survey jointly ... ...

Abstract	Background: In 2016, WHO launched the Global Health Sector Strategy on STIs, 2016-2021 (GHSS) to provide guidance and benchmarks for country achievement by 2020 and four global targets for achievement by 2030. Methods: A country survey jointly developed by experienced technical personnel at WHO Headquarters (HQ) and WHO regional offices was reviewed and distributed by WHO regional advisors to 194 WHO Member States in September-March 2020. The survey sought to assess implementation and prioritization of STI policy, surveillance, service delivery, commodity availability, and surveillance based on targets of the GHSS. Results: A majority (58%, 112/194) of countries returned a completed survey reflecting current (2019) STI activities. The regions with the highest survey completion rates were South-East Asia Region (91%, 10/11), Region of the Americas (71%, 25/35) and Western Pacific Region (67%, 18/27). Having a national STI strategy was reported by 64% (72/112) and performing STI surveillance activities by 88% (97/110) of reporting countries. Availability of STI services within primary health clinics was reported by 88% of countries (99/112); within HIV clinics by 92% (103/112), and within reproductive health services by 85% (95/112). Existence of a national strategy to eliminate mother-to-child transmission of HIV and syphilis (EMTCT) was reported by 70% of countries (78/112). Antimicrobial resistance (AMR) monitoring for gonococcal infection (gonorrhoea) was reported by 64% (57/89) of reporting countries with this laboratory capacity. Inclusion of HPV vaccine for young women in the national immunization schedule was reported by 59% (65/110) and availability of cervical cancer screening was reported by 91% (95/104). Stockouts of STI medicines, primarily benzathine penicillin, within the prior four years were reported by 34% (37/110) of countries. Conclusions: Mechanisms to support improvements to STI service delivery through national-level policy, commitment, programming and surveillance are needed to operationalize, accelerate and monitor progress towards achievement of the 2030 global STI strategy targets.
MeSH term(s)	Early Detection of Cancer ; Female ; Global Health ; Gonorrhea/epidemiology ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; Humans ; Infectious Disease Transmission, Vertical ; Sexually Transmitted Diseases/diagnosis ; Sexually Transmitted Diseases/epidemiology ; Sexually Transmitted Diseases/prevention & control ; Uterine Cervical Neoplasms ; World Health Organization
Language	English
Publishing date	2022-05-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0263550
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Evidence does not exist that dyspepsia heralds gastric cancer in its earliest stage.

Low-Beer, T S

BMJ (Clinical research ed.)

1999 Volume 318, Issue 7193, Page(s) 1288

MeSH term(s)	Dyspepsia/etiology ; Humans ; Stomach Neoplasms/complications
Language	English
Publishing date	1999-05-08
Publishing country	England
Document type	Comment ; Letter
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8138 ; 0959-8154 ; 0959-8146 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8138 ; 0959-8154 ; 0959-8146 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj.318.7193.1288
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: How the colon begets gallstones.

Low-Beer, T S

Lancet (London, England)

1998 Volume 351, Issue 9103, Page(s) 612–613

MeSH term(s)	Bile/physiology ; Cholelithiasis/physiopathology ; Colon/physiopathology ; Gastrointestinal Transit ; Humans
Language	English
Publishing date	1998-02-28
Publishing country	England
Document type	Journal Article
ZDB-ID	3306-6
ISSN	1474-547X ; 0140-6736 ; 0023-7507
ISSN (online)	1474-547X
ISSN	0140-6736 ; 0023-7507
DOI	10.1016/S0140-6736(05)78424-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.5: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 94: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of the Zimbabwe HIV case surveillance pilot project, 2019.

Nsubuga, Peter / Mabaya, Simbarashe / Apollo, Tsitsi / Sithole, Ngwarai / Komtenza, Brian / Matare, Takura / Chimwaza, Anesu / Takarinda, Kudakwashe / Moyo, Brian / Mbano, Leon / Choto, Regis / Moyo, Thandekile / Lowrance, David / Low-Beer, Daniel / Mugurungi, Owen / Gasasira, Alex

The Pan African medical journal

2020 Volume 37, Page(s) 353

Abstract: Zimbabwe has a high burden of HIV (i.e., estimated 1.3 million HIV-infected and 13.8% HIV incidence in 2017). In 2017, the country developed and implemented a pilot of HIV case surveillance (CS) based on the 2017 World Health Organisation (WHO) person- ... ...

Abstract	Zimbabwe has a high burden of HIV (i.e., estimated 1.3 million HIV-infected and 13.8% HIV incidence in 2017). In 2017, the country developed and implemented a pilot of HIV case surveillance (CS) based on the 2017 World Health Organisation (WHO) person-centred HIV patient monitoring (PM) and case surveillance guidelines. At the end of the pilot phase an evaluation was conducted to inform further steps. The pilot was conducted in two districts (i.e., Umzingwane in Matabeleland South Province and Mutare in Manicaland Province) from August 2017 to December 2018. A mixed-methods cross-sectional study of stakeholders and health facility staff was used to assess the design and operations, performance, usefulness, sustainability, and scalability of the CS system. A total of 13 stakeholders responded to an online questionnaire, while 33 health facility respondents were interviewed in 11 health facilities in the two districts. The HIV CS system was adequately designed for Zimbabwe's context, integrated within existing health information systems at the facility level. However, the training was minimal, and an opportunity to train the data entry clerks in data analysis was missed. The system performed well in terms of surveillance and informatics attributes. However, viral load test results return was a significant problem. The HIV CS system was found useful at the health facility level and should be rolled out in a phased manner, beginning in Manicaland and Matabeleland South provinces. An electronic link needs to be made between the health facilities and the laboratory to reduce viral load test results delays.
MeSH term(s)	Cross-Sectional Studies ; HIV Infections/epidemiology ; HIV Infections/virology ; Humans ; Pilot Projects ; Public Health Surveillance ; Surveys and Questionnaires ; Viral Load ; Zimbabwe/epidemiology
Language	English
Publishing date	2020-12-17
Publishing country	Uganda
Document type	Journal Article
ZDB-ID	2514347-5
ISSN	1937-8688 ; 1937-8688
ISSN (online)	1937-8688
ISSN	1937-8688
DOI	10.11604/pamj.2020.37.353.25600
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Forecasting the global demand for HIV monitoring and diagnostic tests: A 2016-2021 analysis.

Habiyambere, V / Dongmo Nguimfack, B / Vojnov, L / Ford, N / Stover, J / Hasek, L / Maggiore, P / Low-Beer, D / Pérez Gonzàlez, M / Edgil, D / Williams, J / Kuritsky, J / Hargreaves, S / NeSmith, T

PloS one

2018 Volume 13, Issue 9, Page(s) e0201341

Abstract: ... monitor treatment adherence in low and middle-income countries (LMICs). Robust projections of future ...

Abstract	Introduction: Despite considerable progress, just over half of the 37 million people eligible to start antiretroviral therapy (ART) have accessed treatment and millions of HIV-positive people still do not know their status. With demand for ART continuing to grow, meeting the ambitious 90-90-90 HIV treatment targets will depend on improved access to high-quality diagnostics to both diagnose infection and monitor treatment adherence in low and middle-income countries (LMICs). Robust projections of future demand for CD4, viral load (VL), HIV early-infant-diagnosis (EID) tests and HIV rapid diagnostic tests (RDTs) are needed as scale-up continues. Methods: We estimate the current coverage for HIV diagnostics and project future demand to 2021 using a consolidated forecast using data on past coverage and current demand from a number of sources, from 130 predominantly LMIC countries. Results: We forecast that the overall number of CD4 tests is expected to decline between now and 2021 as more countries adopt test-and-treat and shift to VL testing for patient monitoring. Our consolidated forecast projects a gradual decline in demand for CD4 tests to 16.6 million by 2021. We anticipate that demand for VL tests will increase to 28.5 million by 2021, reflecting the increasing number of people who will receive ART and the adoption of VL testing for patient monitoring. We expect that the demand for EID tests will grow more rapidly than in past years, driven by the implementation of testing at birth in programmes globally, in line with WHO guideline recommendations, doubling to 2.1 million tests by 2021. Demand for rapid diagnostic tests is also likely to increase, reaching 509 million tests by 2021. Discussion: In order to achieve the ambitious 90-90-90 targets, it will be essential to maintain and improve access to CD4, VL, EID tests and RDTs. These projections provide insight into the global demand we can expect to see for these HIV monitoring and diagnostic tests, both in relation to historical trends, and the 90-90-90 targets. Our projections will better enable producers to ensure adequate supply, and to support procurement organisations in planning future funding and purchase plans to meet the anticipated demand. The findings highlight the ongoing need for governments and international funding bodies to prioritise improving capacity and access to HIV diagnostic and monitoring technologies in line with demand.
MeSH term(s)	Anti-Retroviral Agents/therapeutic use ; Databases, Factual ; Epidemiological Monitoring ; Female ; Forecasting ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV-1 ; Humans ; Male ; Models, Biological ; Monitoring, Physiologic
Chemical Substances	Anti-Retroviral Agents
Language	English
Publishing date	2018-09-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0201341
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Author Correction: Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets.

Kim, In-Jeong / Lanthier, Paula A / Clark, Madeline J / De La Barrera, Rafael A / Tighe, Michael P / Szaba, Frank M / Travis, Kelsey L / Low-Beer, Timothy C / Cookenham, Tres S / Lanzer, Kathleen G / Bernacki, Derek T / Johnson, Lawrence L / Schneck, Amanda A / Ross, Corinna N / Tardif, Suzette D / Layne-Colon, Donna / Mdaki, Stephanie D / Dick, Edward J / Chuba, Colin /

Gonzalez, Olga / Brasky, Kathleen M / Dutton, John / Rutherford, Julienne N / Coffey, Lark L / Singapuri, Anil / Martin, Claudia Sanchez San / Chiu, Charles Y / Thomas, Stephen J / Modjarrad, Kayvon / Patterson, Jean L / Blackman, Marcia A

NPJ vaccines

2022 Volume 7, Issue 1, Page(s) 99

Language	English
Publishing date	2022-08-20
Publishing country	England
Document type	Published Erratum
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-022-00520-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets.

NPJ vaccines

2022 Volume 7, Issue 1, Page(s) 9

Abstract: Zika virus (ZIKV) is a mosquito-borne arbovirus that can cause severe congenital birth defects. The utmost goal of ZIKV vaccines is to prevent both maternal-fetal infection and congenital Zika syndrome. A Zika purified inactivated virus (ZPIV) was ... ...

Abstract	Zika virus (ZIKV) is a mosquito-borne arbovirus that can cause severe congenital birth defects. The utmost goal of ZIKV vaccines is to prevent both maternal-fetal infection and congenital Zika syndrome. A Zika purified inactivated virus (ZPIV) was previously shown to be protective in non-pregnant mice and rhesus macaques. In this study, we further examined the efficacy of ZPIV against ZIKV infection during pregnancy in immunocompetent C57BL6 mice and common marmoset monkeys (Callithrix jacchus). We showed that, in C57BL/6 mice, ZPIV significantly reduced ZIKV-induced fetal malformations. Protection of fetuses was positively correlated with virus-neutralizing antibody levels. In marmosets, the vaccine prevented vertical transmission of ZIKV and elicited neutralizing antibodies that remained above a previously determined threshold of protection for up to 18 months. These proof-of-concept studies demonstrate ZPIV's protective efficacy is both potent and durable and has the potential to prevent the harmful consequence of ZIKV infection during pregnancy.
Language	English
Publishing date	2022-01-27
Publishing country	England
Document type	Journal Article
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-021-00426-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED